Show Notes
PsychopharmaPearls is NEI's focused podcast series highlighting the clinical insights that can sharpen your prescribing decisions. In this episode, Dr. Andy Cutler talks with Dr. Lisa Harding about how to choose between IV ketamine and intranasal esketamine for patients with difficult-to-treat depression. They unpack the differences that truly matter in practice—from patient selection and monitoring to access, cost, and common missteps. Tune in for practical pearls you can immediately apply to select the right treatment for the right patient.
Lisa Harding, MD is a board-certified psychiatrist and nationally recognized depression specialist with deep expertise in interventional psychiatry. She has performed more than 4,000 procedures, including electroconvulsive therapy (ECT), intravenous ketamine, intranasal esketamine, and transcranial magnetic stimulation (TMS). Dr. Harding is known for her thoughtful approach to complex, treatment-resistant depression, integrating advanced somatic therapies, psychopharmacology, and psychotherapy. She serves as an Assistant Clinical Professor of Psychiatry at Yale University in New Haven, Connecticut.
Andrew J. Cutler, MD is a leading psychiatrist, psychopharmacology expert, and clinical researcher with decades of experience in CNS drug development. As Chief Medical Officer of Neuroscience Education Institute and EMA Wellness, he brings frontline clinical insight together with deep knowledge of the evidence base. Dr. Cutler is widely recognized for translating research into practical guidance for everyday practice and serves as a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.
Resources
Sanacora G et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017;74(4):399-405. doi:10.1001/jamapsychiatry.2017.0080
McIntyre RS et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry 2021;178(5):383-399. doi:10.1176/appi.ajp.2020.20081251
Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26 Register today at nei.global/spring
Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast
Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp
Stay updated with email alerts and join our conversations on social. Follow us on:
YouTube: https://nei.global/youtube
Instagram: https://nei.global/instagram
LinkedIn: https://nei.global/linkedin
Facebook: https://nei.global/facebook
More from NEI Podcast
In this episode, Dr. Andy Cutler talks with Dr. Jon Grant about how compulsivity presents across obsessive-compulsive disorder (OCD), trichotillomania, and skin-picking disorder (excoriation disorder). They discuss how clinicians can distinguish OCD compulsions from body-focused repetitive behaviors and choose among treatments such as exposure and response prevention, habit-reversal training, medication, and emerging treatment approaches.
Originally released in 2022, this episode of The PsychopharmaStahlogy Show features Drs. Andrew Cutler and Stephen Stahl in conversation with Dr. Tiffany Greenwood on the genetic and trait-based links between bipolar disorder and creativity. They explore how temperament, personality, and cognitive style may occupy the space between madness and genius, the role of dopamine, evolutionary explanations for why bipolar risk persists, and why stabilizing mood doesn't have to mean losing creativity.
Originally released in 2024, this episode features the late Dr. Vladimir Maletic in conversation with Drs. Andy Cutler and Stephen Stahl about the clinical significance and neurobiology of anhedonia. They discuss its different dimensions, how it differs from emotional blunting, its relationship to functioning and treatment response, and practical approaches to assessment and treatment. The episode highlights why recovery from depression requires restoring interest, motivation, and pleasure—not simply reducing negative symptoms.
In this episode, Dr. Andy Cutler speaks with Dr. Tim Wilens about the complex relationship between attention-deficit/hyperactivity disorder (ADHD) and substance use disorders. They discuss how to distinguish ADHD from substance-related cognitive symptoms, determine when co-occurring conditions should be treated concurrently, and select appropriate ADHD medications based on the substance involved. Dr. Wilens also examines stimulant misuse and diversion, the role of nonstimulants, what is known about centanafadine's abuse potential, and practical approaches to monitoring treatment without undermining the therapeutic relationship.
Originally released in 2021, this episode features Dr. Thomas Schwartz discussing common mistakes in psychopharmacology and how psychiatric clinicians can recognize and manage them. He explores diagnostic uncertainty, medication dosing, informed consent and monitoring, and rational versus irrational polypharmacy. He also considers how clinicians can reassess inherited diagnoses, learn from prescribing errors, and preserve the therapeutic relationship when mistakes occur.